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geneic transplant due to older age, comorbidities or lack of HLA-
identical donor. Median age at transplant was 52 years (range
37–68), median interval between ﬁrst and second autograft was 26
months (range 3–73). Eleven patients had persistent or progressive
disease at transplant. Twenty patients received high-dose melpha-
lan alone or in combination, while 2 received a combination of
thiotepa, busulfan and cyclophosphamide. Patients had received an
average of 6 prior chemotherapy regimens. Cytogenetic studies
were available in 18/22 patients at the time of transplant, 12 were
normal and 6 abnormal. Results: 14 of the 21 evaluable patients
(70%) achieved a response (1 CR, 13 PR). After a median fol-
low-up of 15 months (2–82), 1 year progression-free survival (PFS)
was 40% and 1-year overall survival (OS) was 78%. 100-day TRM
was 0%. Median PFS was 10 months, and median OS has not been
reached. On univariate analysis, abnormal cytogenetics at trans-
plant was a predictor of shorter overall survival (P  .01). Con-
clusions: In patients with progressive disease after an autologous
transplant, salvage autologous transplants may achieve responses in
70% of patients with durable remissions in a small subset. Normal
cytogenetics at second transplant predicts a longer survival.
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Background: Autologous peripheral blood stem cell transplan-
tation is at the present the therapy of choice for the treatment of
multiple myeloma (MM) patients younger than 70 years old.
Methods: Between August 1993 and November 2004, ﬁfty four
patients with MM were autografted; median age was 49 years
(range 20–69). Patients were given a median of 4.3  106/Kg
CD34 () viable MNC after conditioning with high-dose melpha-
lan regimens (oral or I.V. in 47 and 7 patients, respectively).
Results: Median time to achieve 	 0.5  109/L granulocytes was
12 days, whereas median time to achieve 	20  109/L platelets
was 15 days. Thirty seven patients are alive 15 to 157 months after
the autograft (median 86 months). The 7-year disease-free and
overall post-transplant survival is 24% and 60%, respectively. The
transplant-related mortality was 13%. Seven patients died as a
result of the toxicity of the conditioning regimen, whereas death in
the remaining 10 cases was related to post-transplant relapse of the
malignancy. Four good-prognostic factors were identiﬁed: interval
between diagnosis and transplant less than 24 months, number of
prior chemotherapy regimens 2, remission status (complete or
partial), and pretransplant 2microglobulin less than 3 mg/dL.
Conclusions: Autologous peripheral blood stem cell transplanta-
tion using oral melphalan was a good choice of treatment for
Mexican multiple myeloma patients. Transplant-related mortality
was higher in comparison with other studies.
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DRAMATIC IMPROVEMENT OF POEMS SYNDROME BY STEM CELL
TRANSPLANTATION PARALLELS DECREASE IN VEGF AND BFGF LEVEL
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Purpose: POEMS syndrome is a rare disease characterized by
polyneuropathy, organomegaly, endocrinopathy, M-protein, and
skin changes. We treated a severely ill woman with a 4-year history
of polyneuropathy showing all signs of a POEMS syndrome. Re-
sponse to chemotherapy including high-dose melphalan treatment
and autologous stem cell transplantation was monitored and vas-
cular endothelial growth factor (VEGF) as well as basic ﬁbroblast
growth factor (bFGF) levels were measured. Methods: Blood
investigation was done for serum electrophoresis analysis and anal-
ysis of VEGF, bFGF, and IL-6 by ELISA. Bone marrow biopsy
specimen was investigated immunohistochemically for IgA, IgG,
kappa, lambda, CD20, CD56, cyclin D1, and VEGF. Results:
Immunohistochemical investigation of the bone marrow biopsy
showed an inﬁltration of IgA and lambda positive plasma cells
(10%). Only few plasma cells expressed kappa. The tumor cell were
negative for CD20, CD56, and cyclin D1, but positive for VEGF
in line with the high VEGF levels in the blood. Blood investigation
revealed a discrete monoclonal gammopathy of IgA lambda type.
Initially, high level of VEGF (1468.7 pg/ml) and bFGF (112.9
pg/ml) were detected. However, treatment with high-dose mel-
phalan and tandem autologous stem cell transplantation proved
extremely helpful in disease control. Already after the ﬁrst trans-
plant the patient started again walking and lost her pulmonary
hypertension. In parallel VEGF and bFGF levels decreased and the
performance status of the patient improved dramatically. Conclu-
sions: VEGF and bFGF measurement is a useful tool for moni-
toring disease activity in POEMS syndrome. Moreover, although
stem cell transplantation is of utmost importance even in patients
with severely reduced performance status, these pathophysiologic
ﬁndings may provide a rational for additional treatment ap-
proaches with anti-angiogenetic substances.
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Introduction: Bone Marrow Transplant (BMT) from related
HLA identical donor (RID) is the treatment of choice for patients
with severe combined immuno-deﬁciency (SCID). In the absence
of RID, bone marrow from HLA haplo-identical (half) related
donors (HID) have often been used. However, HID is frequently
associated with reduced survival and failure of long-term immune
reconstitution. HLA matched unrelated donors (MUD) represent
another promising alternative for patients with SCID. Methods:
We studied hematopoietic engraftment, occurrence of graft versus
host disease, infections and other complication, and survival in
infants diagnosed with SCID who received MUD BMT between
1990 and 2004 in a Canadian pediatric referral center specializing
in such procedures. Detailed evaluations of immune reconstitution
were performed in children that survived more than 2 years after
transplant. Results: During the 14 years of this study, 22 infants
underwent MUD BMT in our center. Molecular diagnosis was
available in 64% of them. All infants received myelo-ablative con-
ditioning pre-transplant. Despite prophylaxis with cyclosporine
and methylprednisolone, acute graft versus host disease occurred in
15 of the 22 patients, and it was the most common cause of death.
All patients developed complete donor lymphocyte engraftment.
None of the 15 patients who are two or more years after transplant
requires intravenous immunoglobulin replacement therapy. After
discontinuing immune suppression all patients have normal T cell
function and T cell repertoire, which is sustained for more than 14
years of follow up. Current survival is 73% and it is even better for
patients with mutations in the IL-2 receptor pathway. Further-
more, survival of patients who presented with low B cells, previ-
ously estimated to have unfavorable outcome, is not signiﬁcantly
lower than in other forms of SCID in this study. Conclusions:
MUD BMT leads to long term survival, engraftment, and immune
function in SCID patients and should be the preferred treatment
for clinically stable infants who do not have a related HLA-iden-
tical donor.
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